Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CRBU

CRBU - Caribou Biosciences, Inc. Stock Price, Fair Value and News

1.80USD-0.13 (-6.74%)Market Closed

Market Summary

CRBU
USD1.80-0.13
Market Closed
-6.74%

CRBU Stock Price

View Fullscreen

CRBU RSI Chart

CRBU Valuation

Market Cap

162.6M

Price/Earnings (Trailing)

-1.41

Price/Sales (Trailing)

4.9

EV/EBITDA

-1.15

Price/Free Cashflow

-1.43

CRBU Price/Sales (Trailing)

CRBU Profitability

EBT Margin

-307.31%

Return on Equity

-33.58%

Return on Assets

-28.33%

Free Cashflow Yield

-69.87%

CRBU Fundamentals

CRBU Revenue

Revenue (TTM)

33.2M

Rev. Growth (Yr)

-30.64%

Rev. Growth (Qtr)

-31.73%

CRBU Earnings

Earnings (TTM)

-115.3M

Earnings Growth (Yr)

-47.03%

Earnings Growth (Qtr)

-19.5%

Breaking Down CRBU Revenue

Last 7 days

-7.7%

Last 30 days

-50.5%

Last 90 days

-66.5%

Trailing 12 Months

-60.9%

How does CRBU drawdown profile look like?

CRBU Financial Health

Current Ratio

10.49

CRBU Investor Care

Shares Dilution (1Y)

47.18%

Diluted EPS (TTM)

-1.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202433.2M000
202314.7M034.2M34.4M
202210.7M13.4M12.7M13.9M
202112.2M5.2M8.0M9.6M
20207.4M9.1M10.7M12.4M
20190005.8M

Tracking the Latest Insider Buys and Sells of Caribou Biosciences, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 20, 2024
khan ruhi ahmad
acquired
-
-
33,000
chief business officer
Feb 20, 2024
o'byrne jason
acquired
-
-
33,000
chief financial officer
Feb 20, 2024
kanner steven
acquired
-
-
33,000
chief scientific officer
Feb 20, 2024
haurwitz rachel e.
acquired
-
-
118,700
president and ceo
Feb 20, 2024
mcclung barbara g
acquired
-
-
33,000
chief legal officer
Feb 06, 2024
kanner steven
acquired
82,252
2.69
30,577
chief scientific officer
Jun 08, 2023
haurwitz rachel e.
acquired
29,600
2.96
10,000
president and ceo
Mar 20, 2023
haurwitz rachel e.
acquired
29,600
2.96
10,000
president and ceo
Jan 19, 2023
rizvi syed ali-aamir
sold
-35,506
6.31
-5,627
chief medical officer
Dec 02, 2022
kanner steven
acquired
57,568
2.69
21,401
chief scientific officer

1–10 of 36

Which funds bought or sold CRBU recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 06, 2024
WESTWOOD HOLDINGS GROUP INC
reduced
-9.28
-295,000
1,293,000
0.01%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
-98,000
666,000
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.48
28,503
87,503
0.01%
May 20, 2024
Virtu Financial LLC
added
395
327,000
422,000
0.03%
May 17, 2024
Artal Group S.A.
unchanged
-
-62,516
541,484
0.01%
May 17, 2024
Rokos Capital Management LLP
unchanged
-
-500,174
4,304,030
0.02%
May 16, 2024
Ancora Advisors LLC
new
-
102,800
102,800
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.9
-34,894
42,318
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-46.46
-340,462
314,666
-%
May 16, 2024
FSA Wealth Management LLC
new
-
10,177
10,177
-%

1–10 of 47

Are Funds Buying or Selling CRBU?

Are funds buying CRBU calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRBU
No. of Funds

Unveiling Caribou Biosciences, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 23, 2024
point72 asset management, l.p.
4.5%
3,958,535
SC 13G
Feb 14, 2024
point72 asset management, l.p.
4.0%
3,521,376
SC 13G/A
Feb 14, 2024
pfm health sciences, lp
7.3%
6
SC 13G/A
Jan 25, 2024
state street corp
5.79%
5,119,666
SC 13G/A
Jan 25, 2024
blackrock inc.
8.0%
7,068,468
SC 13G/A
Jan 08, 2024
avidity partners management lp
7.2%
6,360,212
SC 13G
Jul 20, 2023
point72 asset management, l.p.
4.5%
3,610,739
SC 13G
Jul 10, 2023
pfizer inc
7.1%
4,690,431
SC 13G
Feb 14, 2023
pfm health sciences, lp
7.3%
6
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A

Recent SEC filings of Caribou Biosciences, Inc.

View All Filings
Date Filed Form Type Document
Jun 14, 2024
8-K
Current Report
Jun 03, 2024
8-K
Current Report
May 07, 2024
8-K
Current Report
May 07, 2024
10-Q
Quarterly Report
Apr 25, 2024
DEFA14A
DEFA14A
Apr 25, 2024
DEF 14A
DEF 14A
Apr 25, 2024
ARS
ARS
Apr 04, 2024
8-K
Current Report
Mar 11, 2024
S-8
Employee Benefits Plan
Mar 11, 2024
8-K
Current Report

Peers (Alternatives to Caribou Biosciences, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Caribou Biosciences, Inc. News

Latest updates
Simply Wall St05 Jun 202412:29 pm
The Motley Fool3 months ago

Caribou Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Revenue-31.7%2,429,0003,558,00023,662,0003,502,0003,692,0003,303,0004,192,0002,664,0002,559,0003,977,0001,476,0001,586,000984,0001,198,0008,478,0001,701,000-
Operating Expenses18.1%48,431,00041,000,00038,295,00034,618,00034,270,00029,840,00032,623,00023,517,00022,964,00022,593,00017,440,00014,761,00016,195,0009,427,00010,733,00012,130,000-
  S&GA Expenses50.6%14,643,0009,721,0009,711,0008,909,0008,534,0009,849,00010,044,0009,593,0007,853,0006,760,0005,113,0004,596,0004,171,0003,247,0003,153,0003,489,000-
  R&D Expenses8.0%33,788,00031,279,00028,584,00025,709,00025,736,00019,991,00022,579,00013,924,00015,111,00015,833,00012,327,00010,165,00012,024,0006,180,0007,580,0008,641,000-
EBITDA Margin-3.7%-2.96-2.86-2.81-6.63-7.06-5.13-4.88-6.14-6.84-7.80-9.49-3.05-2.85----
Interest Expenses---------1,000-2,0004,0006,0006,0005,000--
Income Taxes-100.0%-23,000--70,000---315,500----354,000-213,000-50,000-1,202,000-
Earnings Before Taxes------45,908,000----18,158,000-20,974,000-14,311,000-13,159,000-15,057,000-8,146,000-1,922,000-11,002,000-
EBT Margin-3.8%-3.07-2.96-2.91-6.76-7.17-5.24-4.97-6.24-6.94-7.91-9.66-3.13-2.92----
Net Income-19.5%-41,234,000-34,505,000-10,002,000-28,044,000-26,989,000-26,647,000-26,697,000-19,088,000-18,479,000-20,974,000-14,311,000-13,159,000-14,703,000-7,933,000-1,872,000-9,800,000-
Net Income Margin-17.2%-3.48-2.97-2.77-7.38-7.18-7.15-6.36-6.82-6.97-7.87-9.55-3.08-2.78----
Free Cashflow-63.4%-38,648,000-23,656,000-33,528,000-29,931,000-26,801,000-23,730,000-24,493,000-22,396,000-22,074,000-15,897,000-16,960,00020,291,000-8,103,000----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q4
Assets-5.9%40743245835034737439942144644246215836.00
  Current Assets-10.1%30533935126923926030735336839144914324.00
    Cash Equivalents-3.4%49.0051.0010466.0053.0058.0082.0011214824043513016.00
  Net PPE4.9%19.0018.0017.0015.0013.0011.009.008.006.005.004.004.004.00
Liabilities-0.4%64.0064.0059.0080.0069.0073.0075.0073.0074.0055.0058.0056.0018.00
  Current Liabilities2.5%29.0028.0025.0034.0027.0028.0029.0029.0027.0026.0026.0026.0012.00
Shareholder's Equity-6.8%343368398269278301324348372388404--
  Retained Earnings-13.8%-340-299-264-254-225-197-170-143-116-97.79-79.30-58.30-30.87
  Additional Paid-In Capital2.5%68466866452550450049649349048648411.007.00
Shares Outstanding2.1%90.0088.0088.0066.0061.0061.0061.0061.0061.0060.0022.0010.00-
Float----263---308---538-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Cashflow From Operations-74.0%-37,200-21,379-28,812-15,161-27,939-25,044-22,376-21,873-21,673-21,389-14,967-16,47620,313-8,076-8,691--
  Share Based Compensation12.1%3,9883,5563,4783,5853,1313,1012,6732,9183,0241,578935593343231248--
Cashflow From Investing172.9%22,956-31,474-68,47611,06420,7031,170-8,339-13,973-72,107-173,961-1,930-484-22.00-600-4.00--
Cashflow From Financing29134.9%12,485-43.00135,12817,5711,642127654362990460322,683606109,68082.00112--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CRBU Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue$ 2,429$ 3,502
Operating expenses:  
Research and development33,78825,709
General and administrative14,6438,909
Total operating expenses48,43134,618
Loss from operations(46,002)(31,116)
Other income (expense):  
Change in fair value of equity securities0(15)
Change in fair value of MSKCC success payments liability303255
Other income, net4,4652,832
Total other income4,7683,072
Net loss(41,234)(28,044)
Other comprehensive income (loss):  
Net unrealized (loss) gain on available-for-sale marketable securities, net of tax(352)788
Net comprehensive loss$ (41,586)$ (27,256)
Net loss per share, basic (in dollars per share)$ (0.46)$ (0.46)
Net loss per share, diluted (in dollars per share)$ (0.46)$ (0.46)
Weighted-average common shares outstanding, basic (in shares)89,302,93761,186,514
Weighted-average common shares outstanding, diluted (in shares)89,302,93761,186,514

CRBU Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS  
Cash and cash equivalents$ 49,400$ 51,162
Marketable securities, short-term244,588277,665
Accounts receivable917148
Contract assets9711,425
Other receivables1,7252,286
Prepaid expenses and other current assets6,9136,155
Total current assets304,514338,841
NON-CURRENT ASSETS  
Investments in equity securities7,7537,753
Marketable securities, long-term51,93843,577
Property and equipment, net19,16718,270
Operating lease, right of use assets21,65922,182
Other assets1,7941,586
TOTAL ASSETS406,825432,209
CURRENT LIABILITIES  
Accounts payable5,9403,120
Accrued expenses and other current liabilities18,99021,135
Operating lease liabilities, current1,2641,200
Deferred revenue ($2,487 and $2,487 from related party, respectively)2,8272,847
Total current liabilities29,02128,302
LONG-TERM LIABILITIES  
Deferred revenue, net of current portion ($3,108 and $3,730 from related party, respectively)5,4286,102
MSKCC success payments liability2,6362,939
Operating lease liabilities, non-current25,89525,908
Deferred tax liabilities556557
Total liabilities63,53663,808
COMMITMENTS AND CONTINGENCIES (Note 9)
STOCKHOLDERS’ EQUITY  
Common stock, par value $0.0001 per share, 300,000,000 shares authorized at March 31, 2024, and December 31, 2023, respectively; 90,314,501 and $88,448,948 shares issued and outstanding as of March 31, 2024, and December 31, 2023, respectively98
Additional paid-in-capital684,121667,648
Accumulated other comprehensive (loss) income(322)30
Accumulated deficit(340,519)(299,285)
Total stockholders’ equity343,289368,401
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 406,825$ 432,209
CRBU
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
 CEO
 WEBSITEhttps://cariboubio.com
 INDUSTRYBiotechnology
 EMPLOYEES137

Caribou Biosciences, Inc. Frequently Asked Questions


What is the ticker symbol for Caribou Biosciences, Inc.? What does CRBU stand for in stocks?

CRBU is the stock ticker symbol of Caribou Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Caribou Biosciences, Inc. (CRBU)?

As of Fri Jun 14 2024, market cap of Caribou Biosciences, Inc. is 162.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRBU stock?

You can check CRBU's fair value in chart for subscribers.

What is the fair value of CRBU stock?

You can check CRBU's fair value in chart for subscribers. The fair value of Caribou Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Caribou Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRBU so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Caribou Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether CRBU is over valued or under valued. Whether Caribou Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Caribou Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRBU.

What is Caribou Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, CRBU's PE ratio (Price to Earnings) is -1.41 and Price to Sales (PS) ratio is 4.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRBU PE ratio will change depending on the future growth rate expectations of investors.